Neuroprotective therapy and physical factors evaluated for rehabilitative treatment of non-proliferative diabetic retinopathy

Diabetic retinopathy (DR) is a leading cause of vision loss globally, characterized by progressive damage to the retinal microvasculature. While traditionally viewed as a microvascular disease, emerging evidence highlights neurodegeneration as an early and critical event in its pathophysiology, often preceding overt vascular changes. Current standard-of-care treatments primarily target late-stage vascular complications, such as laser photocoagulation or anti-VEGF injections, which can stabilize vision but do not address the underlying neurodegenerative processes or prevent early onset. This leaves a significant therapeutic gap for patients with non-proliferative DR (NPDR), where neuronal dysfunction and loss are already occurring, contributing to visual impairment and disease progression. Investigating neuroprotective strategies, potentially combined with physical factors, offers a promising avenue to intervene earlier, preserve retinal neurons, and improve long-term visual outcomes by targeting this crucial, often overlooked, aspect of DR.

This study aimed to evaluate the effectiveness of a neuroprotective agent combined with pre-formed physical factors for the rehabilitative treatment of patients with non-proliferative diabetic retinopathy. The investigation included 114 patients (totaling 228 eyes) ranging in age from 42 to 70 years, all diagnosed with diabetes mellitus and non-proliferative diabetic retinopathy. The abstract, however, does not specify the exact nature or dosage of the neuroprotective agent, the type of physical factors applied, the treatment duration, frequency, or the primary endpoints measured. The study design appears to be an interventional clinical evaluation, but specific protocols or assay names are not provided.

The provided abstract does not contain specific results, numerical data, or statistical outcomes from the study. It outlines the objective and patient cohort but does not present any findings regarding the effectiveness of the neuroprotective agent or the combined therapy with physical factors on diabetic retinopathy progression, visual acuity, or any other measured parameters. Therefore, no specific percentages, p-values, fold-changes, or other quantitative data can be reported from the abstract provided. No specific pathways like NF-κB or mTORC1 were mentioned as being modulated, nor were any receptor interactions like GLP-1R discussed in the context of findings.